Jeil Pharmaceutical to Exclusively Sell Allergy Treatments Zyrtec and Seezal

[Asia Economy Reporter Myunghwan Lee] Jeil Pharmaceutical will sell the allergy treatments 'Cizal' and 'Zyrtec.'

Jeil Pharmaceutical announced on the 10th that it has signed an exclusive domestic sales contract with Korea UCB Pharma for 'Cizal Tablets,' 'Cizal Liquid,' and 'Zyrtec 100 Tablets,' and will begin supplying them to the domestic market.

Zyrtec is a representative antihistamine sold in over 60 countries. It is indicated for allergic rhinitis, chronic idiopathic urticaria, dermatitis accompanied by itching, as well as eczema.

Cizal is a prescription drug developed by isolating the R-enantiomer cetirizine, the active isomer primarily responsible for the efficacy of cetirizine, the main ingredient of Zyrtec, with similar drug components and effects to Zyrtec. As a result, it has the advantage of rapid onset and long-lasting effects. Cizal is available in two formulations: tablet form 'Cizal Tablets' and liquid form 'Cizal Liquid,' allowing prescriptions for various age groups.

According to the pharmaceutical market research firm Ubist, the current domestic antihistamine market is approximately 170 billion KRW in size. Among this, Cizal is the top-selling drug in general hospitals and private clinics, widely used as an allergy treatment for many patients.

Kim Yuhyang, PM at Jeil Pharmaceutical, said, "We will strengthen our partnership through continuous communication and solution provision with Korea UCB Pharma," adding, "We will strive to expand the supply chain so that more allergy patients can lead healthy lives through excellent pharmaceuticals."

Korea UCB Pharma stated, "We have reached a turning point by establishing a new partnership after 10 years," and added, "Through this collaboration, we will enhance the delivery of academic value and actively engage in marketing activities to ensure more patients can benefit."

This content was produced with the assistance of AI translation services.